Navigation Links
Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
Date:3/17/2011

CHICAGO, March 17, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and webcast discussing the Company's 2010 fourth quarter and full-year financial results on Thursday, March 24, 2011 at 9:00 AM (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well as other members of the management team, will also present an update on the Company. A press release reporting the 2010 fourth quarter and full-year results will be issued before the U.S. stock markets open on Thursday, March 24, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-713-4211 (domestic) or 617-213-4864 (international). The passcode for the conference call is 86880056. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PAVMV3UD3.

Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

A replay of the conference call will be available until March 31, 2011. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75965641.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
2. Greg Miller of Advanced Health Media Named New Jersey Technology Council CIO of the Year
3. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
4. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
5. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
8. New materials may bring advanced optical technologies, cloaking
9. Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP
10. Advanced BioHealing to Present at 29th Annual J.P. Morgan Healthcare Conference
11. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March 24, ... Maxwell Biotech Venture Fund (MBVF), today announced positive results ... to the standard drug therapy regimen in patients with ... molecule drug discovered by scientists at Sequella, Inc. ( ... of Health. A total of 140 ...
(Date:3/24/2017)... Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company ... vaccines, today announced participation at the following conferences: ... and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at ... New York, NY . Agenus will participate in ... am: Robert B. Stein , M.D., Ph.D., President, ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
Breaking Biology News(10 mins):